FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.’s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
The major regulatory milestone marks a significant advancement for individuals suffering from this rare and debilitating autoimmune condition, which causes severe inflammation and tissue remodeling around the eyes.
The company is preparing for an immediate commercial rollout.
Read Next
Biotech
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian may have edge over Amgen in eye drug showdown, analysts argue
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
FDA approves Lumvoa for thyroid eye disease
Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa
New Drug Approved for Thyroid Eye Disease
FDA grants priority review to Enspryng for thyroid eye disease
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to…
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion…
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease,…
Viridian Therapeutics has scored an FDA
Veligrotug labeling shows data for both the active and chronic forms of TED
